Savefor later Page saved! You can go back to this later in your Diabetes and Me Close

Diabetes Research Steering Group 2: Type 1 treatments and prevention

Current priorities:

  • Beta cell regeneration
  • Closed loop, pump, and CGM technology
  • C-peptide and glucose variability - residual insulin production
  • Glucagon and its role in type 1 diabetes
  • Hormones in type 1 diabetes
  • Insulin resistance in type 1 diabetes
  • Mental health and type 1 diabetes
  • Prevention and population screening
  • Patient Reported Outcome Measures (PROMs) and quality of life

Chair: Professor Colin Dayan, Cardiff University

Professor Dayan has a long established interest in the underlying biology of type 1 diabetes and is currently conducting early phase clinical trials in the development of type 1 diabetes immunotherapy. 

Who's involved?

  • Associate Professor Ramzi Ajjan, Deputy Chair
  • Becki Millar
  • David Dupont
  • Hannah Sutton
  • Alex Clarke
  • Sarah Jarrett
  • Andrew Brasher
  • Elaine Hibbert-Jones
  • Dr Ildem Akerman
  • Dr James Cantley
  • James Shaw
  • Dr Jill Carlton
  • Professor Parth Narendran

If you would like to share your views with the group on where research into prevention, targets and therapies for type 1 diabetes should be focused, please get in touch:

Back to Top
Brand Icons/Telephonecheck - FontAwesomeicons/tickicons/uk